Here are the S-1 registration statements from POLOMAR HEALTH SVCS INC (PMHS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow PMHS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMHS filings page.
Polomar Health Services, Inc. filed Amendment No. 2 to its Form S-1 registration statement, allowing a proposed public sale of its securities from time to time after the statement becomes effective. The amendment details estimated offering-related expenses of $30,000, including a Securities and Exchange Commission registration fee of $860.83, along with accounting, legal, and miscellaneous costs.
The company explains broad indemnification protections for its directors and officers under Nevada law and its bylaws, and notes that it maintains director and officer liability insurance. It also discloses recent unregistered issuances, including 10,000,000 shares of common stock issued on September 12, 2024 upon conversion of 500,000 shares of Series A preferred stock, and approximately 207,414,147 shares of common stock issued as of September 30, 2024 to former Polomar members in connection with an acquisition, all relying on Section 4(a)(2) of the Securities Act.
Polomar Health Services, Inc. has filed an amended Form S-1 to register up to 7,710,219 shares of common stock for resale by existing selling stockholders. The company will not receive any proceeds from these sales; all net proceeds go to the selling stockholders. Shares may be sold at a fixed price of $0.20 until an exchange or OTCQX/OTCQB listing, versus a recent OTCID Basic Market bid of $0.08 on December 5, 2025.
Polomar operates a licensed compounding pharmacy in Florida focused on dermatology, GLP‑1 weight‑loss drugs and erectile dysfunction therapies, and plans digital platforms such as SlimRx and PoloMeds. It relies on a licensed inhalable drug IP portfolio from Pinata Holdings and an exclusivity‑based fulfillment agreement with ForHumanity that includes a $750,000 guaranteed payment and revenue thresholds for extended exclusivity.
The business is development stage, with a history of losses, heavy related‑party debt at 12%+ rates, and going‑concern risks. A planned merger with Altanine would leave Altanine holders owning about 80% of the combined company, subject to audits, SEC and Nasdaq approvals, a reverse split to a $10.00 share price, and supermajority stockholder consent. The filing highlights regulatory, IP, financing, dilution and penny‑stock trading risks, as well as potential price pressure from selling stockholder resales.